Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies

Progress in Neurobiology

Volumn 155, Issue , 2017, Pages 171-193

  Bourdenx, Mathieu ^a,b   Koulakiotis, Nikolaos Stavros ^c   Sanoudou, Despina ^d   Bezard, Erwan ^a,b   Dehay, Benjamin ^a,b   Tsarbopoulos, Anthony ^c,d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c Goulandris Natural History Museum   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alzheimer's disease; Neurodegeneration; Parkinson's disease; Protein aggregation; Spreading; Therapeutic

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOPATHY; CELL DEATH; CELL MEMBRANE; DEGENERATIVE DISEASE; HUMAN; MICROGLIA; MOLECULAR DYNAMICS; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN STRUCTURE; REVIEW; SYNUCLEINOPATHY; TAUOPATHY; ANIMAL; METABOLISM; PATHOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; PROTEIN AGGREGATION, PATHOLOGICAL; TAUOPATHIES;

EID: 84937804600     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2015.07.003     Document Type: Review

References (396)

1. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D., Rosenthal, A., Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000), 239–252.
2. Abraha, A., Ghoshal, N., Gamblin, T.C., Cryns, V., Berry, R.W., Kuret, J., Binder, L.I., C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J. Cell Sci. 113:Pt 21 (2000), 3737–3745.
3. Aguzzi, A., Calella, A.M., Prions: protein aggregation and infectious diseases. Physiol. Rev. 89 (2009), 1105–1152.
4. Ahmed, Z., Cooper, J., Murray, T.K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M.A., Cavallini, A., Jackson, S., Bose, S., Clavaguera, F., Tolnay, M., Lavenir, I., Goedert, M., Hutton, M.L., O'Neill, M.J., A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127 (2014), 667–683.
5. Aliev, G., Smith, M.A., Seyidova, D., Neal, M.L., Lamb, B.T., Nunomura, A., Gasimov, E.K., Vinters, H.V., Perry, G., LaManna, J.C., Friedland, R.P., The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. 12 (2002), 21–35.
6. Alvarez-Erviti, L., Seow, Y., Schapira, A.H., Gardiner, C., Sargent, I.L., Wood, M.J., Cooper, J.M., Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 42 (2011), 360–367.
7. Anandatheerthavarada, H.K., Biswas, G., Robin, M.-A., Avadhani, N.G., Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol. 161 (2003), 41–54.
8. Andreadis, A., Brown, W.M., Kosik, K.S., Structure and novel exons of the human tau gene. Biochemistry 31 (1992), 10626–10633.
9. Anglade, P., Vyas, S., Hirsch, E.C., Agid, Y., Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol. 12 (1997), 603–610.
10. Area-Gomez, E., Del Carmen Lara Castillo, M., Tambini, M.D., Guardia-Laguarta, C., de Groof, A.J., Madra, M., Ikenouchi, J., Umeda, M., Bird, T.D., Sturley, S.L., Schon, E.A., Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31 (2012), 4106–4123.
11. Arendt, T., Stieler, J., Strijkstra, A.M., Hut, R.A., Rudiger, J., Van der Zee, E.A., Harkany, T., Holzer, M., Hartig, W., Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals. J. Neurosci. 23 (2003), 6972–6981.
12. Auluck, P.K., Bonini, N.M., Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8 (2002), 1185–1186.
13. Auluck, P.K., Caraveo, G., Lindquist, S., alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 26 (2010), 211–233.
14. Auluck, P.K., Chan, H.Y., Trojanowski, J.Q., Lee, V.M., Bonini, N.M., Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295 (2002), 865–868.
15. Bae, E.J., Lee, H.J., Rockenstein, E., Ho, D.H., Park, E.B., Yang, N.Y., Desplats, P., Masliah, E., Lee, S.J., Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32 (2012), 13454–13469.
16. Bai, G., Chivatakarn, O., Bonanomi, D., Lettieri, K., Franco, L., Xia, C.H., Stein, E., Ma, L., Lewcock, J.W., Pfaff, S.L., Presenilin-dependent receptor processing is required for axon guidance. Cell 144 (2011), 106–118.
17. Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J., Bruton, C.J., Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int. J. Exp. Pathol. 74 (1993), 441–454.
18. Baker, H.F., Ridley, R.M., Duchen, L.W., Crow, T.J., Bruton, C.J., Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol. Neurobiol. 8 (1994), 25–39.
19. Baker, M., Litvan, I., Houlden, H., Adamson, J., Dickson, D., Perez-Tur, J., Hardy, J., Lynch, T., Bigio, E., Hutton, M., Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8 (1999), 711–715.
20. Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., Jones, E., Alzheimer's disease. Lancet 377 (2011), 1019–1031.
21. Bartels, A.L., Leenders, K.L., Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov. Disord.: Off. J. Mov. Disord. Soc. 22 (2007), 1852–1856.
22. Bartels, T., Choi, J.G., Selkoe, D.J., alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 (2011), 107–110.
23. Bazoti, F.N., Bergquist, J., Markides, K., Tsarbopoulos, A., Localization of the noncovalent binding site between amyloid-beta-peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry. J. Am. Soc. Mass Spectrom. 19 (2008), 1078–1085.
24. Bazoti, F.N., Bergquist, J., Markides, K.E., Tsarbopoulos, A., Noncovalent interaction between amyloid-beta-peptide (1–40) and oleuropein studied by electrospray ionization mass spectrometry. J. Am. Soc. Mass Spectrom. 17 (2006), 568–575.
25. Bazoti, F.N., Tsarbopoulos, A., Markides, K.E., Bergquist, J., Study of the non-covalent interaction between amyloid-beta-peptide and melatonin using electrospray ionization mass spectrometry. J. Mass Spectrom. 40 (2005), 182–192.
26. Becker, R.E., Greig, N.H., Increasing the success rate for Alzheimer's disease drug discovery and development. Expert Opin. Drug Discov. 7 (2012), 367–370.
27. Behl, C., Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. 57 (1999), 301–323.
28. Bennett, M.C., Bishop, J.F., Leng, Y., Chock, P.B., Chase, T.N., Mouradian, M.M., Degradation of alpha-synuclein by proteasome. J. Biol. Chem. 274 (1999), 33855–33858.
29. Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., Wszolek, Z., Ashe, K., Knight, J., Dickson, D., Andorfer, C., Rosenberry, T.L., Lewis, J., Hutton, M., Janus, C., Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci. 27 (2007), 3650–3662.
30. Berriman, J., Serpell, L.C., Oberg, K.A., Fink, A.L., Goedert, M., Crowther, R.A., Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 9034–9038.
31. Berry, R.W., Abraha, A., Lagalwar, S., LaPointe, N., Gamblin, T.C., Cryns, V.L., Binder, L.I., Inhibition of tau polymerization by its carboxy-terminal caspase cleavage fragment. Biochemistry 42 (2003), 8325–8331.
32. Bertram, L., Tanzi, R.E., The genetic epidemiology of neurodegenerative disease. J. Clin. Investig. 115 (2005), 1449–1457.
33. Bezard, E., Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. Lancet Neurol., 2, 2003, 393.
34. Bieschke, J., Russ, J., Friedrich, R.P., Ehrnhoefer, D.E., Wobst, H., Neugebauer, K., Wanker, E.E., EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 7710–7715.
35. Billings, L.M., Oddo, S., Green, K.N., McGaugh, J.L., LaFerla, F.M., Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 (2005), 675–688.
36. Bisaglia, M., Tessari, I., Mammi, S., Bubacco, L., Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease. Neuromol. Med. 11 (2009), 239–251.
37. Blair, J.A., Siedlak, S.L., Wolfram, J.A., Nunomura, A., Castellani, R.J., Ferreira, S.T., Klein, W.L., Wang, Y., Casadesus, G., Smith, M.A., Perry, G., Zhu, X.W., Lee, H.G., Accumulation of intraneuronal amyloid-beta is common in normal brain. Curr. Alzheimer Res. 11 (2014), 317–324.
38. Blandini, F., Neural and immune mechanisms in the pathogenesis of Parkinson's disease. J. Neuroimmune Pharmacol. 8 (2013), 189–201.
39. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., Riederer, P., Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202 (1995), 17–20.
40. Bondareff, W., Harrington, C., Wischik, C.M., Hauser, D.L., Roth, M., immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 53 (1994), 158–164.
41. Bourdenx, M., Bezard, E., Dehay, B., Lysosomes and alpha-synuclein form a dangerous duet leading to neuronal cell death. Front. Neuroanat., 8, 2014, 83.
42. Bourdenx, M., Dehay, B., Bezard, E., Down-regulating alpha-synuclein for treating synucleopathies. Mov. Disord.: Off. J. Mov. Disord. Soc. 29 (2014), 1463–1465.
43. Bourdenx, M., Dutheil, N., Bezard, E., Dehay, B., Systemic gene delivery to the central nervous system using Adeno-associated virus. Front. Mol. Neurosci., 7, 2014, 50.
44. Bove, J., Martinez-Vicente, M., Dehay, B., Perier, C., Recasens, A., Bombrun, A., Antonsson, B., Vila, M., BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy 10 (2014), 889–900.
45. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991), 239–259.
46. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N., Braak, E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003), 197–211.
47. Bramblett, G.T., Goedert, M., Jakes, R., Merrick, S.E., Trojanowski, J.Q., Lee, V.M., Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10 (1993), 1089–1099.
48. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Investig. 119 (2009), 182–192.
49. Brunden, K.R., Trojanowski, J.Q., Lee, V.M.Y., Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 8 (2009), 783–793.
50. Brundin, P., Li, J.Y., Holton, J.L., Lindvall, O., Revesz, T., Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 9 (2008), 741–745.
51. Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J.S., Taddei, N., Ramponi, G., Dobson, C.M., Stefani, M., Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002), 507–511.
52. Buchhave, P., Minthon, L., Zetterberg, H., Wallin, Å.K., Blennow, K., Hansson, O., Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5–10 years before the onset of alzheimer dementia. Arch. Gen. Psychiatry 69 (2012), 98–106.
53. Buell, A.K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T.P., Linse, S., Dobson, C.M., Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 7671–7676.
54. Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., Sudhof, T.C., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329 (2010), 1663–1667.
55. Butner, K.A., Kirschner, M.W., Tau protein binds to microtubules through a flexible array of distributed weak sites. J. Cell Biol. 115 (1991), 717–730.
56. Buttner, S., Habernig, L., Broeskamp, F., Ruli, D., Vogtle, F.N., Vlachos, M., Macchi, F., Kuttner, V., Carmona-Gutierrez, D., Eisenberg, T., Ring, J., Markaki, M., Taskin, A.A., Benke, S., Ruckenstuhl, C., Braun, R., Van den Haute, C., Bammens, T., van der Perren, A., Frohlich, K.U., Winderickx, J., Kroemer, G., Baekelandt, V., Tavernarakis, N., Kovacs, G.G., Dengjel, J., Meisinger, C., Sigrist, S.J., Madeo, F., Endonuclease G mediates alpha-synuclein cytotoxicity during Parkinson's disease. EMBO J. 32 (2013), 3041–3054.
57. Cabin, D.E., Shimazu, K., Murphy, D., Cole, N.B., Gottschalk, W., McIlwain, K.L., Orrison, B., Chen, A., Ellis, C.E., Paylor, R., Lu, B., Nussbaum, R.L., Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22 (2002), 8797–8807.
58. Caughey, B., Baron, G.S., Chesebro, B., Jeffrey, M., Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu. Rev. Biochem. 78 (2009), 177–204.
59. Cedazo-Mínguez, A., Popescu, B.O., Blanco-Millán, J.M., Akterin, S., Pei, J.J., Winblad, B., Cowburn, R.F., Apolipoprotein E and β-amyloid (1-42) regulation of glycogen synthase kinase-3β. J. Neurochem. 87 (2003), 1152–1164.
60. Chakrabarty, P., Li, A., Ceballos-Diaz, C., Eddy, J.A., Funk, C.C., Moore, B., DiNunno, N., Rosario, A.M., Cruz, P.E., Verbeeck, C., Sacino, A., Nix, S., Janus, C., Price, N.D., Das, P., Golde, T.E., IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85 (2015), 519–533.
61. Cheruvara, H., Allen-Baume, V.L., Kad, N.M., Mason, J.M., Intracellular screening of a peptide library to derive a potent peptide inhibitor of alpha-synuclein aggregation. J. Biol. Chem. 290:12 (2015), 7426–7435.
62. Chu, Y., Mickiewicz, A.L., Kordower, J.H., alpha-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol. Dis. 41 (2011), 71–82.
63. Chui, D.H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O., Suzuki, H., Araki, W., Inoue, H., Shirotani, K., Takahashi, K., Gallyas, F., Tabira, T., Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat. Med. 5 (1999), 560–564.
64. Cicchetti, F., Lacroix, S., Cisbani, G., Vallieres, N., Saint-Pierre, M., St-Amour, I., Tolouei, R., Skepper, J.N., Hauser, R.A., Mantovani, D., Barker, R.A., Freeman, T.B., Mutant huntingtin is present in neuronal grafts in huntington disease patients. Ann. Neurol. 76:1 (2014), 31–42.
65. Citron, M., Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9 (2010), 387–398.
66. Clavaguera, F., Akatsu, H., Fraser, G., Crowther, R.A., Frank, S., Hench, J., Probst, A., Winkler, D.T., Reichwald, J., Staufenbiel, M., Ghetti, B., Goedert, M., Tolnay, M., Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9535–9540.
67. Clavaguera, F., Bolmont, T., Crowther, R.A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A.K., Beibel, M., Staufenbiel, M., Jucker, M., Goedert, M., Tolnay, M., Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11 (2009), 909–913.
68. Clavaguera, F., Hench, J., Lavenir, I., Schweighauser, G., Frank, S., Goedert, M., Tolnay, M., Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127 (2014), 299–301.
69. Cole, N.B., Dieuliis, D., Leo, P., Mitchell, D.C., Nussbaum, R.L., Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 314 (2008), 2076–2089.
70. Collinge, J., Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 24 (2001), 519–550.
71. Condello, C., Yuan, P., Schain, A., Grutzendler, J., Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat. Commun., 6, 2015, 6176.
72. Conrad, C., Andreadis, A., Trojanowski, J.Q., Dickson, D.W., Kang, D., Chen, X., Wiederholt, W., Hansen, L., Masliah, E., Thal, L.J., Katzman, R., Xia, Y., Saitoh, T., Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann. Neurol. 41 (1997), 277–281.
73. Conrad, C., Zhu, J., Conrad, C., Schoenfeld, D., Fang, Z., Ingelsson, M., Stamm, S., Church, G., Hyman, B.T., Single molecule profiling of tau gene expression in Alzheimer's disease. J. Neurochem. 103 (2007), 1228–1236.
74. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E., Lansbury, P.T. Jr., Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 571–576.
75. Cookson, M.R., Evolution of neurodegeneration. Curr. Biol. 22 (2012), R753–R761.
76. Cooper, J.M., Wiklander, P.B., Nordin, J.Z., Al-Shawi, R., Wood, M.J., Vithlani, M., Schapira, A.H., Simons, J.P., El-Andaloussi, S., Alvarez-Erviti, L., Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord.: Off. J. Mov. Disord. Soc. 29 (2014), 1476–1485.
77. Cramer, P.E., Cirrito, J.R., Wesson, D.W., Lee, C.Y.D., Karlo, J.C., Zinn, A.E., Casali, B.T., Restivo, J.L., Goebel, W.D., James, M.J., Brunden, K.R., Wilson, D.A., Landreth, G.E., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335 (2012), 1503–1506.
78. Crehan, H., Hardy, J., Pocock, J., Microglia, Alzheimer's disease, and complement. Int. J. Alzheimer's Dis., 2012, 2012, 983640.
79. Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., Clarke, R.W., Dunne, P., Aprile, F.A., Bertoncini, C.W., Wood, N.W., Knowles, T.P., Dobson, C.M., Klenerman, D., Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 149 (2012), 1048–1059.
80. Crowther, R.A., Jakes, R., Spillantini, M.G., Goedert, M., Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436 (1998), 309–312.
81. Crowther, R.A., Olesen, O.F., Smith, M.J., Jakes, R., Goedert, M., Assembly of Alzheimer-like filaments from full-length tau protein. FEBS Lett. 337 (1994), 135–138.
82. Cuervo, A.M., Dice, J.F., Age-related decline in chaperone-mediated autophagy. J. Biol. Chem. 275 (2000), 31505–31513.
83. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., Sulzer, D., Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004), 1292–1295.
84. Daniele, S.G., Beraud, D., Davenport, C., Cheng, K., Yin, H., Maguire-Zeiss, K.A., Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal., 8, 2015, ra45.
85. Dantuma, N.P., Bott, L.C., The ubiquitin–proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front. Mol. Neurosci., 7, 2014, 70.
86. Danzer, K.M., Haasen, D., Karow, A.R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., Kostka, M., Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27 (2007), 9220–9232.
87. Danzer, K.M., Ruf, W.P., Putcha, P., Joyner, D., Hashimoto, T., Glabe, C., Hyman, B.T., McLean, P.J., Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 25 (2011), 326–336.
88. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., Greenberg, M.E., Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997), 231–241.
89. Davidson, W.S., Jonas, A., Clayton, D.F., George, J.M., Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998), 9443–9449.
90. Dawson, T.M., Ko, H.S., Dawson, V.L., Genetic animal models of Parkinson's disease. Neuron 66 (2010), 646–661.
91. de Calignon, A., Fox, L.M., Pitstick, R., Carlson, G.A., Bacskai, B.J., Spires-Jones, T.L., Hyman, B.T., Caspase activation precedes and leads to tangles. Nature 464 (2010), 1201–1204.
92. de Calignon, A., Polydoro, M., Suarez-Calvet, M., William, C., Adamowicz, D.H., Kopeikina, K.J., Pitstick, R., Sahara, N., Ashe, K.H., Carlson, G.A., Spires-Jones, T.L., Hyman, B.T., Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73 (2012), 685–697.
93. Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., Bjorklund, A., TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E1817–E1826.
94. Dehay, B., Bove, J., Rodriguez-Muela, N., Perier, C., Recasens, A., Boya, P., Vila, M., Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30 (2010), 12535–12544.
95. DeKosky, S.T., Marek, K., Looking backward to move forward: early detection of neurodegenerative disorders. Science 302 (2003), 830–834.
96. DeMattos, R.B., Cirrito, J.R., Parsadanian, M., May, P.C., O'Dell, M.A., Taylor, J.W., Harmony, J.A.K., Aronow, B.J., Bales, K.R., Paul, S.M., Holtzman, D.M., ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that ApoE regulates extracellular Aβ metabolism in vivo. Neuron 41 (2004), 193–202.
97. Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., Lee, S.J., Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 13010–13015.
98. Dettmer, U., Newman, A.J., Luth, E.S., Bartels, T., Selkoe, D., In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J. Biol. Chem. 288 (2013), 6371–6385.
99. Devi, L., Prabhu, B.M., Galati, D.F., Avadhani, N.G., Anandatheerthavarada, H.K., Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J. Neurosci. 26 (2006), 9057–9068.
100. Di Maria, E., Tabaton, M., Vigo, T., Abbruzzese, G., Bellone, E., Donati, C., Frasson, E., Marchese, R., Montagna, P., Munoz, D.G., Pramstaller, P.P., Zanusso, G., Ajmar, F., Mandich, P., Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol. 47 (2000), 374–377.
101. Diepenbroek, M., Casadei, N., Esmer, H., Saido, T.C., Takano, J., Kahle, P.J., Nixon, R.A., Rao, M.V., Melki, R., Pieri, L., Helling, S., Marcus, K., Krueger, R., Masliah, E., Riess, O., Nuber, S., Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]alphaSyn transgenic mice. Hum. Mol. Genet. 23 (2014), 3975–3989.
102. Dikiy, I., Eliezer, D., Folding and misfolding of alpha-synuclein on membranes. Biochim. Biophys. Acta 1818 (2012), 1013–1018.
103. Dinamarca, M.C., Rios, J.A., Inestrosa, N.C., Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease. Front. Physiol., 3, 2012, 464.
104. Doody, R.S., Thomas, R.G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P.S., Siemers, E., Liu-Seifert, H., Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370 (2014), 311–321.
105. Dowding, C.H., Shenton, C.L., Salek, S.S., A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 23 (2006), 693–721.
106. Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B.T., McLean, P.J., Unni, V.K., Distinct roles in vivo for the ubiquitin–proteasome system and the autophagy–lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 31 (2011), 14508–14520.
107. Eckert, A., Hauptmann, S., Scherping, I., Rhein, V., Muller-Spahn, F., Gotz, J., Muller, W.E., Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener. Dis. 5 (2008), 157–159.
108. Eckman, E.A., Eckman, C.B., A beta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33 (2005), 1101–1105.
109. Eisele, Y.S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L.H., Yan, Z.X., Roth, K., Aguzzi, A., Staufenbiel, M., Walker, L.C., Jucker, M., Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 12926–12931.
110. Eisele, Y.S., Fritschi, S.K., Hamaguchi, T., Obermuller, U., Fuger, P., Skodras, A., Schafer, C., Odenthal, J., Heikenwalder, M., Staufenbiel, M., Jucker, M., Multiple factors contribute to the peripheral induction of cerebral beta-amyloidosis. J. Neurosci. 34 (2014), 10264–10273.
111. Eisele, Y.S., Obermuller, U., Heilbronner, G., Baumann, F., Kaeser, S.A., Wolburg, H., Walker, L.C., Staufenbiel, M., Heikenwalder, M., Jucker, M., Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330 (2010), 980–982.
112. El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood, N.J., Gibson, M.J., Curran, M.D., Court, J.A., Mann, D.M., Ikeda, S., Cookson, M.R., Hardy, J., Allsop, D., Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 17 (2003), 1945–1947.
113. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M., Margaritis, L.H., Stefanis, L., Vekrellis, K., Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30 (2010), 6838–6851.
114. Essa, M., Vijayan, R., Castellano-Gonzalez, G., Memon, M., Braidy, N., Guillemin, G., Neuroprotective effect of natural products against Alzheimer's disease. Neurochem. Res. 37 (2012), 1829–1842.
115. Falcon, B., Cavallini, A., Angers, R., Glover, S., Murray, T.K., Barnham, L., Jackson, S., O'Neill, M.J., Isaacs, A.M., Hutton, M.L., Szekeres, P.G., Goedert, M., Bose, S., Conformation determines the seeding potencies of native and recombinant tau aggregates. J. Biol. Chem. 290 (2015), 1049–1065.
116. Fares, M.B., Ait-Bouziad, N., Dikiy, I., Mbefo, M.K., Jovicic, A., Kiely, A., Holton, J.L., Lee, S.J., Gitler, A.D., Eliezer, D., Lashuel, H.A., The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet. 23 (2014), 4491–4509.
117. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., Eckman, C.B., Tanzi, R.E., Selkoe, D.J., Guenette, S., Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4162–4167.
118. Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G.K., Stefanova, N., Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61 (2013), 349–360.
119. Fernandez, J.A., Rojo, L., Kuljis, R.O., Maccioni, R.B., The damage signals hypothesis of Alzheimer's disease pathogenesis. J. Alzheimer's Dis.: JAD 14 (2008), 329–333.
120. Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y.Q., Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., Scazufca, M., Alzheimers Dis, I., Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005), 2112–2117.
121. Forny-Germano, L., Lyra e Silva, N.M., Batista, A.F., Brito-Moreira, J., Gralle, M., Boehnke, S.E., Coe, B.C., Lablans, A., Marques, S.A., Martinez, A.M., Klein, W.L., Houzel, J.C., Ferreira, S.T., Munoz, D.P., De Felice, F.G., Alzheimer's disease-like pathology induced by amyloid-beta oligomers in nonhuman primates. J. Neurosci. 34 (2014), 13629–13643.
122. Fortin, D.L., Troyer, M.D., Nakamura, K., Kubo, S., Anthony, M.D., Edwards, R.H., Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24 (2004), 6715–6723.
123. Fountaine, T.M., Wade-Martins, R., RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res. 85 (2007), 351–363.
124. Fredenburg, R.A., Rospigliosi, C., Meray, R.K., Kessler, J.C., Lashuel, H.A., Eliezer, D., Lansbury, P.T. Jr., The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46 (2007), 7107–7118.
125. Frost, B., Gotz, J., Feany, M.B., Connecting the dots between tau dysfunction and neurodegeneration. Trends Cell Biol. 25 (2015), 46–53.
126. Frost, B., Jacks, R.L., Diamond, M.I., Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284 (2009), 12845–12852.
127. Fu, H., Dirosario, J., Killedar, S., Zaraspe, K., McCarty, D.M., Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood–brain barrier gene delivery. Mol. Ther. 19 (2011), 1025–1033.
128. Galanakis, P.A., Bazoti, F.N., Bergquist, J., Markides, K., Spyroulias, G.A., Tsarbopoulos, A., Study of the interaction between the amyloid beta peptide (1–40) and antioxidant compounds by nuclear magnetic resonance spectroscopy. Biopolymers 96 (2011), 316–327.
129. Galpern, W.R., Lang, A.E., Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol. 59 (2006), 449–458.
130. Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., Miller, R., Berry, R.W., Binder, L.I., Cryns, V.L., Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 10032–10037.
131. Gammon, K., Neurodegenerative disease: brain windfall. Nature 515 (2014), 299–300.
132. Ganguly, A.K., Pramanik, B.N., Chen, G., Tsarbopoulos, A., Applied electrospray mass spectrometry: practical spectroscopy series. Pramanik, B.N., Ganguly, A.K., Gross, M.L., (eds.) Detection of Noncovalent Complexes by Electrospray Ionization Mass Spectrometry, 2002, CRC Press, New York, 367–387.
133. George, J.M., Jin, H., Woods, W.S., Clayton, D.F., Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15 (1995), 361–372.
134. Geula, C., Wu, C.K., Saroff, D., Lorenzo, A., Yuan, M., Yankner, B.A., Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med. 4 (1998), 827–831.
135. Giacobini, E., Becker, R.E., One hundred years after the discovery of ALZHeimer's disease. a turning point for therapy?. J. Alzheimers Dis. 12 (2007), 37–52.
136. Giacobini, E., Gold, G., Alzheimer disease therapy—moving from amyloid-β to tau. Nat. Rev. Neurol. 9 (2013), 677–686.
137. Giasson, B.I., Forman, M.S., Higuchi, M., Golbe, L.I., Graves, C.L., Kotzbauer, P.T., Trojanowski, J.Q., Lee, V.M., Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300 (2003), 636–640.
138. Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., Caldwell, K.A., Caldwell, G.A., Rochet, J.C., McCaffery, J.M., Barlowe, C., Lindquist, S., The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 145–150.
139. Glenner, G.G., Wong, C.W., Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120 (1984), 885–890.
140. Goedert, M., Falcon, B., Clavaguera, F., Tolnay, M., Prion-like mechanisms in the pathogenesis of tauopathies and synucleinopathies. Curr. Neurol. Neurosci. Rep., 14, 2014, 495.
141. Goedert, M., Jakes, R., Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 9 (1990), 4225–4230.
142. Goedert, M., Jakes, R., Crowther, R.A., Six, J., Lubke, U., Vandermeeren, M., Cras, P., Trojanowski, J.Q., Lee, V.M., The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc. Natl. Acad. Sci. U. S. A. 90 (1993), 5066–5070.
143. Goedert, M., Jakes, R., Spillantini, M.G., Hasegawa, M., Smith, M.J., Crowther, R.A., Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383 (1996), 550–553.
144. Goedert, M., Spillantini, M.G., Cairns, N.J., Crowther, R.A., Tau proteins of alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8 (1992), 159–168.
145. Goedert, M., Spillantini, M.G., Del Tredici, K., Braak, H., 100 years of Lewy pathology. Nat. Rev. Neurol. 9 (2013), 13–24.
146. Goldsbury, C., Mocanu, M.M., Thies, E., Kaether, C., Haass, C., Keller, P., Biernat, J., Mandelkow, E., Mandelkow, E.M., Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. Traffic 7 (2006), 873–888.
147. Golombowski, S., MullerSpahn, F., Romig, H., Mendla, K., Hock, C., Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci. Lett. 225 (1997), 213–215.
148. Gomes, G.M., Dalmolin, G.D., Bar, J., Karpova, A., Mello, C.F., Kreutz, M.R., Rubin, M.A., Inhibition of the polyamine system counteracts beta-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors. PLOS ONE, 9, 2014, e99184.
149. Gorbatyuk, O.S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A.S., Sullivan, L.F., Mandel, R.J., Chen, W., Meyers, C., Manfredsson, F.P., Muzyczka, N., In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol. Ther. 18 (2010), 1450–1457.
150. Gousset, K., Schiff, E., Langevin, C., Marijanovic, Z., Caputo, A., Browman, D.T., Chenouard, N., de Chaumont, F., Martino, A., Enninga, J., Olivo-Marin, J.C., Mannel, D., Zurzolo, C., Prions hijack tunnelling nanotubes for intercellular spread. Nat. Cell Biol. 11 (2009), 328–336.
151. Grad, L.I., Guest, W.C., Yanai, A., Pokrishevsky, E., O'Neill, M.A., Gibbs, E., Semenchenko, V., Yousefi, M., Wishart, D.S., Plotkin, S.S., Cashman, N.R., Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16398–16403.
152. Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., Lynch, D.R., Englander, S.W., Axelsen, P.H., Giasson, B.I., The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280 (2005), 7800–7807.
153. Grimm, M.O.W., Grimm, H.S., Patzold, A.J., Zinser, E.G., Halonen, R., Duering, M., Tschape, J.A., De Strooper, B., Muller, U., Shen, J., Hartmann, T., Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7 (2005), 1118–1123.
154. Guardia-Laguarta, C., Area-Gomez, E., Rub, C., Liu, Y., Magrane, J., Becker, D., Voos, W., Schon, E.A., Przedborski, S., alpha-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 34 (2014), 249–259.
155. Guillot-Sestier, M.V., Doty, K.R., Gate, D., Rodriguez, J. Jr., Leung, B.P., Rezai-Zadeh, K., Town, T., Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85 (2015), 534–548.
156. Guo, J.L., Covell, D.J., Daniels, J.P., Iba, M., Stieber, A., Zhang, B., Riddle, D.M., Kwong, L.K., Xu, Y., Trojanowski, J.Q., Lee, V.M., Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154 (2013), 103–117.
157. Haass, C., Selkoe, D.J., Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8 (2007), 101–112.
158. Handoko, M., Grant, M., Kuskowski, M., Zahs, K.R., Wallin, A., Blennow, K., Ashe, K.H., Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. 70 (2013), 594–599.
159. Hansen, C., Angot, E., Bergstrom, A.L., Steiner, J.A., Pieri, L., Paul, G., Outeiro, T.F., Melki, R., Kallunki, P., Fog, K., Li, J.Y., Brundin, P., alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Investig. 121 (2011), 715–725.
160. Hardy, J., The Alzheimer family of diseases: many etiologies, one pathogenesis?. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 2095–2097.
161. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
162. Hardy, J.A., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256 (1992), 184–185.
163. Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., Masliah, E., Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10 (1999), 717–721.
164. Hayashi, T., Fujimoto, M., Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction. Mol. Pharmacol. 77 (2010), 517–528.
165. Hellstrom-Lindahl, E., Ravid, R., Nordberg, A., Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol. Aging 29 (2008), 210–221.
166. Hipp, M.S., Park, S.H., Hartl, F.U., Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol. 24 (2014), 506–514.
167. Hirsch, E.C., Hunot, S., Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 8 (2009), 382–397.
168. Hirsch, E.C., Hunot, S., Faucheux, B., Agid, Y., Mizuno, Y., Mochizuki, H., Tatton, W.G., Tatton, N., Olanow, W.C., Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Disord.: Off. J. Mov. Disord. Soc. 14 (1999), 383–385.
169. Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiol. Aging 26 (2005), 625–635.
170. Holscher, C., Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol. Dis. 5 (1998), 129–141.
171. Howes, M.-J.R., Perry, N.S.L., Houghton, P.J., Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res. 17 (2003), 1–18.
172. Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q., Lee, V.M.Y., Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33 (2013), 1024–1037.
173. Ihara, Y., Morishima-Kawashima, M., Nixon, R., The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harbor Perspect. Med., 2012, 2.
174. Iqbal, K., Zaidi, T., Thompson, C.H., Merz, P.A., Wisniewski, H.M., Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol. (Berl.) 62 (1984), 167–177.
175. Irwin, D.J., Abrams, J.Y., Schonberger, L.B., Leschek, E.W., Mills, J.L., Lee, V.M., Trojanowski, J.Q., Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol. 70 (2013), 462–468.
176. Irwin, D.J., Cohen, T.J., Grossman, M., Arnold, S.E., Xie, S.X., Lee, V.M.Y., Trojanowski, J.Q., Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135 (2012), 807–818.
177. Ittner, L.M., Götz, J., Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12 (2011), 67–72.
178. Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, A., Saitoh, T., The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995), 467–475.
179. Jack, C.R., Lowe, V.J., Weigand, S.D., Wiste, H.J., Senjem, M.L., Knopman, D.S., Shiung, M.M., Gunter, J.L., Boeve, B.F., Kemp, B.J., Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132 (2009), 1355–1365.
180. Jackrel, M.E., DeSantis, M.E., Martinez, B.A., Castellano, L.M., Stewart, R.M., Caldwell, K.A., Caldwell, G.A., Shorter, J., Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156 (2014), 170–182.
181. Jacobsen, J.S., Wu, C.C., Redwine, J.M., Comery, T.A., Arias, R., Bowlby, M., Martone, R., Morrison, J.H., Pangalos, M.N., Reinhart, P.H., Bloom, F.E., Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 5161–5166.
182. Jaworski, T., Kügler, S., Van Leuven, F., Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease. Int. J. Alzheimer's Dis., 2010, 2010.
183. Jeganathan, S., Hascher, A., Chinnathambi, S., Biernat, J., Mandelkow, E.M., Mandelkow, E., Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 283 (2008), 32066–32076.
184. Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y.C., Lu, Y.M., Bhangale, T., Graham, R.R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O.A., Jonsson, E.G., Palotie, A., Behrens, T.W., Magnusson, O.T., Kong, A., Thorsteinsdottir, U., Watts, R.J., Stefansson, K., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 (2012), 96–99.
185. Jucker, M., Walker, L.C., Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70 (2011), 532–540.
186. Jucker, M., Walker, L.C., Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501 (2013), 45–51.
187. Kane, M.D., Lipinski, W.J., Callahan, M.J., Bian, F., Durham, R.A., Schwarz, R.D., Roher, A.E., Walker, L.C., Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J. Neurosci. 20 (2000), 3606–3611.
188. Karpinar, D.P., Balija, M.B., Kugler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N., Kim, H.Y., Taschenberger, G., Falkenburger, B.H., Heise, H., Kumar, A., Riedel, D., Fichtner, L., Voigt, A., Braus, G.H., Giller, K., Becker, S., Herzig, A., Baldus, M., Jackle, H., Eimer, S., Schulz, J.B., Griesinger, C., Zweckstetter, M., Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J. 28 (2009), 3256–3268.
189. Karpova, A., Mikhaylova, M., Bera, S., Bar, J., Reddy, P.P., Behnisch, T., Rankovic, V., Spilker, C., Bethge, P., Sahin, J., Kaushik, R., Zuschratter, W., Kahne, T., Naumann, M., Gundelfinger, E.D., Kreutz, M.R., Encoding and transducing the synaptic or extrasynaptic origin of NMDA receptor signals to the nucleus. Cell 152 (2013), 1119–1133.
190. Kellie, J.F., Higgs, R.E., Ryder, J.W., Major, A., Beach, T.G., Adler, C.H., Merchant, K., Knierman, M.D., Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci. Rep., 4, 2014, 5797.
191. Khodr, C.E., Becerra, A., Han, Y., Bohn, M.C., Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 1550 (2014), 47–60.
192. Khodr, C.E., Sapru, M.K., Pedapati, J., Han, Y., West, N.C., Kells, A.P., Bankiewicz, K.S., Bohn, M.C., An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 1395 (2011), 94–107.
193. Kim, J., Basak, J.M., Holtzman, D.M., The role of apolipoprotein E in Alzheimer's disease. Neuron 63 (2009), 287–303.
194. Kim, Y.E., Hipp, M.S., Bracher, A., Hayer-Hartl, M., Hartl, F.U., Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Biochem. 82 (2013), 323–355.
195. Kimberly, W.T., Zheng, J.B., Town, T., Flavell, R.A., Selkoe, D.J., Physiological regulation of the beta-amyloid precursor protein signaling domain by c-Jun N-terminal kinase JNK3 during neuronal differentiation. J. Neurosci. 25 (2005), 5533–5543.
196. King, M.E., Kan, H.M., Baas, P.W., Erisir, A., Glabe, C.G., Bloom, G.S., Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J. Cell Biol. 175 (2006), 541–546.
197. Klucken, J., Shin, Y., Masliah, E., Hyman, B.T., McLean, P.J., Hsp70 reduces alpha-synuclein aggregation and toxicity. J. Biol. Chem. 279 (2004), 25497–25502.
198. Klyubin, I., Betts, V., Welzel, A.T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C.A., Cullen, W.K., Peng, Y., Wisniewski, T., Selkoe, D.J., Anwyl, R., Walsh, D.M., Rowan, M.J., Amyloid β protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 28 (2008), 4231–4237.
199. Koo, E.H., Kopan, R., Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med. 10 (2004), S26–S33.
200. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., Olanow, C.W., Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14 (2008), 504–506.
201. Kosel, S., Egensperger, R., von Eitzen, U., Mehraein, P., Graeber, M.B., On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. 93 (1997), 105–108.
202. Kosik, K.S., Orecchio, L.D., Bakalis, S., Neve, R.L., Developmentally regulated expression of specific tau sequences. Neuron 2 (1989), 1389–1397.
203. Koulakiotis, N.S., Anagnostopoulos, D., Chalatsa, I., Sanoudou, D., Tsarbopoulos, A., Using Biodiversity for Discovering Potential Anti-Amyloidogenic Agents. Proceedings of the PHARMA2014 Conference, Singapore, 2014, 60–63.
204. Lamberts, J.T., Hildebrandt, E.N., Brundin, P., Spreading of alpha-synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. Neurobiol. Dis. 77 (2015), 276–283.
205. Landman, N., Jeong, S.Y., Shin, S.Y., Voronov, S.V., Serban, G., Kang, M.S., Park, M.K., Di Paolo, G., Chung, S., Kim, T.W., Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 19524–19529.
206. Langbaum, J.B., Fleisher, A.S., Chen, K., Ayutyanont, N., Lopera, F., Quiroz, Y.T., Caselli, R.J., Tariot, P.N., Reiman, E.M., Ushering in the study and treatment of preclinical Alzheimer disease. Nat. Rev. Neurol. 9 (2013), 371–381.
207. Larner, A.J., Doran, M., Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J. Neurol. 253 (2006), 139–158.
208. Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Sengupta, U., Guerrero-Munoz, M.J., Kiritoshi, T., Neugebauer, V., Jackson, G.R., Kayed, R., Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep., 2, 2012, 700.
209. Lashuel, H.A., Hartley, D., Petre, B.M., Walz, T., Lansbury, P.T., Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 418, 2002, 291.
210. Lee, B.H., Lee, M.J., Park, S., Oh, D.C., Elsasser, S., Chen, P.C., Gartner, C., Dimova, N., Hanna, J., Gygi, S.P., Wilson, S.M., King, R.W., Finley, D., Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467 (2010), 179–184.
211. Lee, H.J., Patel, S., Lee, S.J., Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25 (2005), 6016–6024.
212. Lee, H.J., Suk, J.E., Patrick, C., Bae, E.J., Cho, J.H., Rho, S., Hwang, D., Masliah, E., Lee, S.J., Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285 (2010), 9262–9272.
213. Lee, K.W., Chen, W., Junn, E., Im, J.Y., Grosso, H., Sonsalla, P.K., Feng, X., Ray, N., Fernandez, J.R., Chao, Y., Masliah, E., Voronkov, M., Braithwaite, S.P., Stock, J.B., Mouradian, M.M., Enhanced phosphatase activity attenuates alpha-synucleinopathy in a mouse model. J. Neurosci. 31 (2011), 6963–6971.
214. Lee, V.M., Brunden, K.R., Hutton, M., Trojanowski, J.Q., Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb. Perspect Med., 1, 2011, a006437.
215. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, K., Durr, A., Melki, R., Verny, C., Brice, A., French Parkinson's Disease Genetics Study, G., G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 73 (2013), 459–471.
216. Li, J.Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn, N.P., Rehncrona, S., Bjorklund, A., Widner, H., Revesz, T., Lindvall, O., Brundin, P., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14 (2008), 501–503.
217. Li, S., Hong, S., Shepardson, N.E., Walsh, D.M., Shankar, G.M., Selkoe, D., Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62 (2009), 788–801.
218. Li, W., Hoffman, P.N., Stirling, W., Price, D.L., Lee, M.K., Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations. J. Neurochem. 88 (2004), 401–410.
219. Li, W.W., Yang, R., Guo, J.C., Ren, H.M., Zha, X.L., Cheng, J.S., Cai, D.F., Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 18 (2007), 1543–1546.
220. Lin, H., Bhatia, R., Lal, R., Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 15 (2001), 2433–2444.
221. Lin, M.T., Beal, M.F., Alzheimer's APP mangles mitochondria. Nat. Med. 12 (2006), 1241–1243.
222. Liu, C.W., Giasson, B.I., Lewis, K.A., Lee, V.M., Demartino, G.N., Thomas, P.J., A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280 (2005), 22670–22678.
223. Liu, D.M., Jin, L., Wang, H., Zhao, H.Y., Zhao, C.L., Yang, H., RNA interference mediated silencing of alpha-synuclein in MN9D cells and its effects on cell viability. Neurosci. Bull. 24 (2008), 96–104.
224. Liu, L., Drouet, V., Wu, J.W., Witter, M.P., Small, S.A., Clelland, C., Duff, K., Trans-synaptic spread of tau pathology in vivo. PLoS ONE, 7, 2012, e31302.
225. Liu, Q., Zerbinatti, C.V., Zhang, J., Hoe, H.S., Wang, B., Cole, S.L., Herz, J., Muglia, L., Bu, G.J., Amyloid precursor protein regulates brain apolipoprotein e and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56 (2007), 66–78.
226. Lo Bianco, C., Shorter, J., Regulier, E., Lashuel, H., Iwatsubo, T., Lindquist, S., Aebischer, P., Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J. Clin. Investig. 118 (2008), 3087–3097.
227. Loo, J.A., Electrospray ionization mass spectrometry: a technology for studying noncovalent macromolecular complexes. Int. J. Mass spectrom. 200 (2000), 175–186.
228. Lovestone, S., Hartley, C.L., Pearce, J., Anderton, B.H., Phosphorylation of tau by glycogen synthase kinase-3β in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience 73 (1996), 1145–1157.
229. Lu, P.J., Wulf, G., Zhou, X.Z., Davies, P., Lu, K.P., The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399 (1999), 784–788.
230. Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., Lee, V.M., Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (2012), 949–953.
231. Luk, K.C., Song, C., O'Brien, P., Stieber, A., Branch, J.R., Brunden, K.R., Trojanowski, J.Q., Lee, V.M., Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 20051–20056.
232. Ma, H., Lesne, S., Kotilinek, L., Steidl-Nichols, J.V., Sherman, M., Younkin, L., Younkin, S., Forster, C., Sergeant, N., Delacourte, A., Vassar, R., Citron, M., Kofuji, P., Boland, L.M., Ashe, K.H., Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 8167–8172.
233. Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., Miyasaka, T., Murayama, S., Ikai, A., Takashima, A., Granular tau oligomers as intermediates of tau filaments. Biochemistry 46 (2007), 3856–3861.
234. Maetzler, W., Berg, D., Schalamberidze, N., Melms, A., Schott, K., Mueller, J.C., Liaw, L., Gasser, T., Nitsch, C., Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol. Dis. 25 (2007), 473–482.
235. Maji, S.K., Perrin, M.H., Sawaya, M.R., Jessberger, S., Vadodaria, K., Rissman, R.A., Singru, P.S., Nilsson, K.P., Simon, R., Schubert, D., Eisenberg, D., Rivier, J., Sawchenko, P., Vale, W., Riek, R., Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325 (2009), 328–332.
236. Malagelada, C., Jin, Z.H., Jackson-Lewis, V., Przedborski, S., Greene, L.A., Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 30 (2010), 1166–1175.
237. Malek, N., Swallow, D., Grosset, K.A., Anichtchik, O., Spillantini, M., Grosset, D.G., Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease – a systematic review. Acta Neurol. Scand. 130:2 (2014), 59–72.
238. Mandelkow, E.M., Stamer, K., Vogel, R., Thies, E., Mandelkow, E., Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24 (2003), 1079–1085.
239. Martinez-Vicente, M., Cuervo, A.M., Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 6 (2007), 352–361.
240. Martins, I.C., Kuperstein, I., Wilkinson, H., Maes, E., Vanbrabant, M., Jonckheere, W., Van Gelder, P., Hartmann, D., D'Hooge, R., De Strooper, B., Lipids revert inert Ab amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 27 (2008), 224–233.
241. Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., Games, D., Schenk, D., Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46 (2005), 857–868.
242. Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T.T., Mueller-Steiner, S., Seubert, P., Barbour, R., McConlogue, L., Buttini, M., Games, D., Schenk, D., Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE, 6, 2011, e19338.
243. Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N., Beyreuther, K., Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J. 4 (1985), 2757–2763.
244. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L., Beyreuther, K., Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 4245–4249.
245. Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D.M., Hasegawa, M., Prion-like spreading of pathological alpha-synuclein in brain. Brain 136 (2013), 1128–1138.
246. Mattson, M.P., Magnus, T., Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7 (2006), 278–294.
247. Maurer, K., Volk, S., Gerbaldo, H., Auguste D and Alzheimer's disease. Lancet 349 (1997), 1546–1549.
248. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., Krainc, D., Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146 (2011), 37–52.
249. Mbefo, M.K., Fares, M.B., Paleologou, K., Oueslati, A., Yin, G., Tenreiro, S., Pinto, M., Outeiro, T., Zweckstetter, M., Masliah, E., Lashuel, H.A., Parkinson disease mutant E46K enhances alpha-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo. J. Biol. Chem. 290 (2015), 9412–9427.
250. McCormack, A.L., Mak, S.K., Henderson, J.M., Bumcrot, D., Farrer, M.J., Di Monte, D.A., Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE, 5, 2010, e12122.
251. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988), 1285–1291.
252. McGeer, P.L., McGeer, E.G., NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging 28 (2007), 639–647.
253. Mendez, I., Vinuela, A., Astradsson, A., Mukhida, K., Hallett, P., Robertson, H., Tierney, T., Holness, R., Dagher, A., Trojanowski, J.Q., Isacson, O., Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 14 (2008), 507–509.
254. Mercado, G., Valdes, P., Hetz, C., An ERcentric view of Parkinson's disease. Trends Mol. Med. 19 (2013), 165–175.
255. Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A.L., Vigouret, J.M., Paganetti, P., Walsh, D.M., Mathews, P.M., Ghiso, J., Staufenbiel, M., Walker, L.C., Jucker, M., Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313 (2006), 1781–1784.
256. Miners, J.S., Van Helmond, Z., Chalmers, K., Wilcock, G., Love, S., Kehoe, P.G., Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 65 (2006), 1012–1021.
257. Mishizen-Eberz, A.J., Guttmann, R.P., Giasson, B.I., Day, G.A. 3rd, Hodara, R., Ischiropoulos, H., Lee, V.M., Trojanowski, J.Q., Lynch, D.R., Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86 (2003), 836–847.
258. Mochizuki, H., Hayakawa, H., Migita, M., Shibata, M., Tanaka, R., Suzuki, A., Shimo-Nakanishi, Y., Urabe, T., Yamada, M., Tamayose, K., Shimada, T., Miura, M., Mizuno, Y., An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 10918–10923.
259. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., Nagatsu, T., Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994), 208–210.
260. Morales, I., Farias, G., Maccioni, R.B., Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. Neuroimmunomodulation 17 (2010), 202–204.
261. Morfini, G.A., Burns, M., Binder, L.I., Kanaan, N.M., LaPointe, N., Bosco, D.A., Brown, R.H. Jr., Brown, H., Tiwari, A., Hayward, L., Edgar, J., Nave, K.A., Garberrn, J., Atagi, Y., Song, Y., Pigino, G., Brady, S.T., Axonal transport defects in neurodegenerative diseases. J. Neurosci. 29 (2009), 12776–12786.
262. Mori, H., Kondo, J., Ihara, Y., Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235 (1987), 1641–1644.
263. Mullane, K., Williams, M., Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?. Biochem. Pharmacol. 85 (2013), 289–305.
264. Munch, C., O'Brien, J., Bertolotti, A., Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 3548–3553.
265. Murphy, D.D., Rueter, S.M., Trojanowski, J.Q., Lee, V.M., Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20 (2000), 3214–3220.
266. Myers, N., Mittermeier, R.A., Mittermeier, C.G., da Fonseca, G.A.B., Kent, J., Biodiversity hotspots for conservation priorities. Nature 403 (2000), 853–858.
267. Myohanen, T.T., Hannula, M.J., Van Elzen, R., Gerard, M., Van Der Veken, P., Garcia-Horsman, J.A., Baekelandt, V., Mannisto, P.T., Lambeir, A.M., A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br. J. Pharmacol. 166 (2012), 1097–1113.
268. Nakamura, K., Greenwood, A., Binder, L., Bigio, E.H., Denial, S., Nicholson, L., Zhou, X.Z., Lu, K.P., Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 149 (2012), 232–244.
269. Nakamura, T., Lipton, S., Redox regulation of mitochondrial fission, protein misfolding, synaptic damage, and neuronal cell death: potential implications for Alzheimer's and Parkinson's diseases. Apoptosis 15 (2010), 1354–1363.
270. Nakata, Y., Yasuda, T., Fukaya, M., Yamamori, S., Itakura, M., Nihira, T., Hayakawa, H., Kawanami, A., Kataoka, M., Nagai, M., Sakagami, H., Takahashi, M., Mizuno, Y., Mochizuki, H., Accumulation of alpha-synuclein triggered by presynaptic dysfunction. J. Neurosci. 32 (2012), 17186–17196.
271. Narkiewicz, J., Giachin, G., Legname, G., In vitro aggregation assays for the characterization of alpha-synuclein prion-like properties. Prion 8 (2014), 19–32.
272. Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., Iwata, N., Saito, T., Saido, T.C., Abeta secretion and plaque formation depend on autophagy. Cell Rep. 5 (2013), 61–69.
273. Nimmrich, V., Grimm, C., Draguhn, A., Barghorn, S., Lehmann, A., Schoemaker, H., Hillen, H., Gross, G., Ebert, U., Bruehl, C., Amyloid beta oligomers (a beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 28 (2008), 788–797.
274. Norris, E.H., Giasson, B.I., Ischiropoulos, H., Lee, V.M., Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 278 (2003), 27230–27240.
275. Nuber, S., Harmuth, F., Kohl, Z., Adame, A., Trejo, M., Schonig, K., Zimmermann, F., Bauer, C., Casadei, N., Giel, C., Calaminus, C., Pichler, B.J., Jensen, P.H., Muller, C.P., Amato, D., Kornhuber, J., Teismann, P., Yamakado, H., Takahashi, R., Winkler, J., Masliah, E., Riess, O., A progressive dopaminergic phenotype associated with neurotoxic conversion of alpha-synuclein in BAC-transgenic rats. Brain 136 (2013), 412–432.
276. Olanow, C.W., Perl, D.P., DeMartino, G.N., McNaught, K.S., Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol. 3 (2004), 496–503.
277. Ono, K., Ikeda, T., Takasaki, J., Yamada, M., Familial Parkinson disease mutations influence alpha-synuclein assembly. Neurobiol. Dis. 43 (2011), 715–724.
278. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Choi, P., Hardy, J., Wolozin, B., alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19 (1999), 5782–5791.
279. Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., Torizuka, T., Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57 (2005), 168–175.
280. Oueslati, A., Schneider, B.L., Aebischer, P., Lashuel, H.A., Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E3945–E3954.
281. Paleologou, K.E., Schmid, A.W., Rospigliosi, C.C., Kim, H.Y., Lamberto, G.R., Fredenburg, R.A., Lansbury, P.T. Jr., Fernandez, C.O., Eliezer, D., Zweckstetter, M., Lashuel, H.A., Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 283 (2008), 16895–16905.
282. Pasinetti, G.M., Novel role of red wine-derived polyphenols in the prevention of Alzheimer's disease dementia and brain pathology: experimental approaches and clinical implications. Planta Med. 78 (2012), 1614–1619.
283. Patrick, G.N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., Tsai, L.-H., Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402 (1999), 615–622.
284. Piguet, F., Sondhi, D., Piraud, M., Fouquet, F., Hackett, N.R., Ahouansou, O., Vanier, M.T., Bieche, I., Aubourg, P., Crystal, R.G., Cartier, N., Sevin, C., Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum. Gene Ther. 23 (2012), 903–914.
285. Pooler, A.M., Phillips, E.C., Lau, D.H., Noble, W., Hanger, D.P., Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14 (2013), 389–394.
286. Poorkaj, P., Bird, T.D., Wijsman, E., Nemens, E., Garruto, R.M., Anderson, L., Andreadis, A., Wiederholt, W.C., Raskind, M., Schellenberg, G.D., Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43 (1998), 815–825.
287. Prabhudesai, S., Sinha, S., Attar, A., Kotagiri, A., Fitzmaurice, A.G., Lakshmanan, R., Ivanova, M.I., Loo, J.A., Klarner, F.G., Schrader, T., Stahl, M., Bitan, G., Bronstein, J.M., A novel “molecular tweezer” inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 9 (2012), 464–476.
288. Price, J.L., Morris, J.C., Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 45 (1999), 358–368.
289. Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H.A., Herms, J., Synapse formation and function is modulated by the amyloid precursor protein. J. Neurosci. 26 (2006), 7212–7221.
290. Prince, M., Albanese, E., Guerchet, M., Prina, M., World Alzheimer Report: Dementia and Risk Reduction: an analysis of protective and modifiable factors. Alzheimer's Dis. Int., 2014.
291. Prince, M., Guerchet, M., Prina, M., Policy Brief for Heads of Government: The Global Impact of Dementia 2013–2050. 2013, Alzheimer Disease International, London, UK.
292. Prince, M., Guerchet, M., Prina, M., Association, B.U.P., World Alzheimer Report 2013: Journey of Caring: An Analysis of Long-Term Care for Dementia., 2013, Alzheimer's Disease International.
293. Prusiner, S.B., Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 13363–13383.
294. Prusiner, S.B., Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336 (2012), 1511–1513.
295. Qiao, L., Hamamichi, S., Caldwell, K.A., Caldwell, G.A., Yacoubian, T.A., Wilson, S., Xie, Z.L., Speake, L.D., Parks, R., Crabtree, D., Liang, Q., Crimmins, S., Schneider, L., Uchiyama, Y., Iwatsubo, T., Zhou, Y., Peng, L., Lu, Y., Standaert, D.G., Walls, K.C., Shacka, J.J., Roth, K.A., Zhang, J., Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol. Brain, 1, 2008, 17.
296. Quist, A., Doudevski, I., Lin, H., Azimova, R., Ng, D., Frangione, B., Kagan, B., Ghiso, J., Lal, R., Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 10427–10432.
297. Rajendran, L., Honsho, M., Zahn, T.R., Keller, P., Geiger, K.D., Verkade, P., Simons, K., Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 11172–11177.
298. Rajendran, L., Knobloch, M., Geiger, K.D., Dienel, S., Nitsch, R., Simons, K., Konietzko, U., Increased Abeta production leads to intracellular accumulation of Abeta in flotillin-1-positive endosomes. Neurodegener. Dis. 4 (2007), 164–170.
299. Ramachandran, G., Udgaonkar, J.B., Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies. Biochemistry 52 (2013), 4107–4126.
300. Rapoport, M., Dawson, H.N., Binder, L.I., Vitek, M.P., Ferreira, A., Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 6364–6369.
301. Recasens, A., Dehay, B., Alpha-synuclein spreading in Parkinson's disease. Front. Neuroanat., 8, 2014, 159.
302. Recasens, A., Dehay, B., Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba, A., Fernagut, P.O., Blesa, J., Parent, A., Perier, C., Farinas, I., Obeso, J.A., Bezard, E., Vila, M., Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75 (2014), 351–362.
303. Reid, W.V., Biodiversity hotspots. Trends Ecol. Evol. 13 (1998), 275–280.
304. Resende, R., Moreira, P.I., Proenca, T., Deshpande, A., Busciglio, J., Pereira, C., Oliveira, C.R., Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic. Biol. Med. 44 (2008), 2051–2057.
305. Retz, W., Gsell, W., Münch, G., Rösler, M., Riederer, P., Free radicals in Alzheimer's disease. Gertz, H.J., Arendt, T., (eds.) Alzheimer's Disease—From Basic Research to Clinical Applications, 1998, Springer Vienna, 221–236.
306. Reynolds, M.R., Reyes, J.F., Fu, Y., Bigio, E.H., Guillozet-Bongaarts, A.L., Berry, R.W., Binder, L.I., Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies. J. Neurosci. 26 (2006), 10636–10645.
307. Ridley, R.M., Baker, H.F., Windle, C.P., Cummings, R.M., Very long term studies of the seeding of beta-amyloidosis in primates. J. Neural Transm. 113 (2006), 1243–1251.
308. Rigacci, S., Stefani, M., Nutraceuticals and amyloid neurodegenerative diseases: a focus on natural phenols. Expert Rev. Neurotherap. 15 (2015), 41–52.
309. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.-Q., Mucke, L., Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316 (2007), 750–754.
310. Rocher, A.B., Crimins, J.L., Amatrudo, J.M., Kinson, M.S., Todd-Brown, M.A., Lewis, J., Luebke, J.I., Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp. Neurol. 223 (2010), 385–393.
311. Rochet, J.C., Hay, B.A., Guo, M., Molecular insights into Parkinson's disease. Prog. Mol. Biol. Transl. Sci. 107 (2012), 125–188.
312. Rockenstein, E., Torrance, M., Adame, A., Mante, M., Bar-on, P., Rose, J.B., Crews, L., Masliah, E., Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27 (2007), 1981–1991.
313. Rosen, R.F., Fritz, J.J., Dooyema, J., Cintron, A.F., Hamaguchi, T., Lah, J.J., LeVine, H. 3rd, Jucker, M., Walker, L.C., Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J. Neurochem. 120 (2012), 660–666.
314. Ross, C.A., Poirier, M.A., Protein aggregation and neurodegenerative disease. Nat. Med. 10 (2004), S10–S17.
315. Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., Dubas, F., Frebourg, T., Campion, D., APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet. 38 (2006), 24–26.
316. Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., McGarvey, N.H., Rutherford, N.J., Ceballos-Diaz, C., Robertson, J., Golde, T.E., Giasson, B.I., Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 127 (2014), 645–665.
317. Salloway, S., Sperling, R., Fox, N.C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L.S., Porsteinsson, A.P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I.C., Liu, E., Grundman, M., Yuen, E., Black, R., Brashear, H.R., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370 (2014), 322–333.
318. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., Bohn, M.C., Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198 (2006), 382–390.
319. Sardiello, M., Palmieri, M., di Ronza, A., Medina, D.L., Valenza, M., Gennarino, V.A., Di Malta, C., Donaudy, F., Embrione, V., Polishchuk, R.S., Banfi, S., Parenti, G., Cattaneo, E., Ballabio, A., A gene network regulating lysosomal biogenesis and function. Science 325 (2009), 473–477.
320. Sarkar, S., Davies, J.E., Huang, Z., Tunnacliffe, A., Rubinsztein, D.C., Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J. Biol. Chem. 282 (2007), 5641–5652.
321. Sato, H., Arawaka, S., Hara, S., Fukushima, S., Koga, K., Koyama, S., Kato, T., Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci. 31 (2011), 16884–16894.
322. Savolainen, M.H., Richie, C.T., Harvey, B.K., Mannisto, P.T., Maguire-Zeiss, K.A., Myohanen, T.T., The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse. Neurobiol. Dis. 68 (2014), 1–15.
323. Schapira, A.H., Olanow, C.W., Greenamyre, J.T., Bezard, E., Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 384 (2014), 545–555.
324. Schmitz, C., Rutten, B.P.F., Pielen, A., Schafer, S., Wirths, O., Tremp, G., Czech, C., Blanchard, V., Multhaup, G., Rezaie, P., Korr, H., Steinbusch, H.W.M., Pradier, L., Bayer, T.A., Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 164 (2004), 1495–1502.
325. Schneider, A., Mandelkow, E., Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5 (2008), 443–457.
326. Schon, E.A., Przedborski, S., Mitochondria: the next (neurode)generation. Neuron 70 (2011), 1033–1053.
327. Schweers, O., Schonbrunn-Hanebeck, E., Marx, A., Mandelkow, E., Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. J. Biol. Chem. 269 (1994), 24290–24297.
328. Selkoe, D.J., Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399 (1999), A23–A31.
329. Sergeant, N., David, J.P., Lefranc, D., Vermersch, P., Wattez, A., Delacourte, A., Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases. FEBS Lett. 412 (1997), 578–582.
330. Serrano-Pozo, A., Frosch, M.P., Masliah, E., Hyman, B.T., Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect Med., 1, 2011, a006189.
331. Settembre, C., Di Malta, C., Polito, V.A., Garcia Arencibia, M., Vetrini, F., Erdin, S., Erdin, S.U., Huynh, T., Medina, D., Colella, P., Sardiello, M., Rubinsztein, D.C., Ballabio, A., TFEB links autophagy to lysosomal biogenesis. Science 332 (2011), 1429–1433.
332. Sevlever, D., Jiang, P., Yen, S.H., Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47 (2008), 9678–9687.
333. Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J., Sabatini, B.L., Natural oligomers of the alzheimer amyloid-β protein induce reversible synapse loss by modulating an nmda-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27 (2007), 2866–2875.
334. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L., Selkoe, D.J., Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14 (2008), 837–842.
335. Shavali, S., Brown-Borg, H.M., Ebadi, M., Porter, J., Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci. Lett. 439 (2008), 125–128.
336. Singh, P.K., Kotia, V., Ghosh, D., Mohite, G.M., Kumar, A., Maji, S.K., Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem. Neurosci. 4 (2013), 393–407.
337. Sinha, G., Roche bets on alpha-synuclein for Parkinson's. Nat. Biotechnol., 32, 2014, 212.
338. Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S., Merlini, G., Saraiva, M.J., Westermark, P., Nomenclature Committee of the International Society of, A., Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19 (2012), 167–170.
339. Small, G.W., The pathogenesis of Alzheimer's disease. J. Clin. Psychiatry 59:Suppl. 9 (1998), 7–14.
340. Small, S.A., Duff, K., Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60 (2008), 534–542.
341. Smith, M.A., Taneda, S., Richey, P.L., Miyata, S., Yan, S.D., Stern, D., Sayre, L.M., Monnier, V.M., Perry, G., Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 5710–5714.
342. Soto, C., Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 4 (2003), 49–60.
343. Souza, J.M., Giasson, B.I., Lee, V.M., Ischiropoulos, H., Chaperone-like activity of synucleins. FEBS Lett. 474 (2000), 116–119.
344. Spencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., Masliah, E., Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29 (2009), 13578–13588.
345. Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol. 12 (2013), 609–622.
346. Spillantini, M.G., Murrell, J.R., Goedert, M., Farlow, M.R., Klug, A., Ghetti, B., Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 7737–7741.
347. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
348. Spires-Jones, T.L., Stoothoff, W.H., de Calignon, A., Jones, P.B., Hyman, B.T., Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci. 32 (2009), 150–159.
349. Sponarova, J., Nystrom, S.N., Westermark, G.T., AA-amyloidosis can be transferred by peripheral blood monocytes. PLoS ONE, 3, 2008, e3308.
350. Stamer, K., Vogel, R., Thies, E., Mandelkow, E., Mandelkow, E.M., Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156 (2002), 1051–1063.
351. Stefanovic, A.N., Stockl, M.T., Claessens, M.M., Subramaniam, V., alpha-Synuclein oligomers distinctively permeabilize complex model membranes. FEBS J. 281 (2014), 2838–2850.
352. Stohr, J., Condello, C., Watts, J.C., Bloch, L., Oehler, A., Nick, M., DeArmond, S.J., Giles, K., DeGrado, W.F., Prusiner, S.B., Distinct synthetic Abeta prion strains producing different amyloid deposits in bigenic mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10329–10334.
353. Stohr, J., Watts, J.C., Mensinger, Z.L., Oehler, A., Grillo, S.K., DeArmond, S.J., Prusiner, S.B., Giles, K., Purified and synthetic Alzheimer's amyloid beta (Abeta) prions. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 11025–11030.
354. Su, X., Federoff, H.J., Maguire-Zeiss, K.A., Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotoxic. Res. 16 (2009), 238–254.
355. Sunderland, T., Mirza, N., Putnam, K.T., Linker, G., Bhupali, D., Durham, R., Soares, H., Kimmel, L., Friedman, D., Bergeson, J., Csako, G., Levy, J.A., Bartko, J.J., Cohen, R.M., Cerebrospinal fluid β-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ɛ4 allele. Biol. Psychiatry 56 (2004), 670–676.
356. Sung, J.Y., Park, S.M., Lee, C.H., Um, J.W., Lee, H.J., Kim, J., Oh, Y.J., Lee, S.T., Paik, S.R., Chung, K.C., Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 280 (2005), 25216–25224.
357. Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M.W., Okamoto, S., Dziewczapolski, G., Nakamura, T., Cao, G., Pratt, A.E., Kang, Y.J., Tu, S., Molokanova, E., McKercher, S.R., Hires, S.A., Sason, H., Stouffer, D.G., Buczynski, M.W., Solomon, J.P., Michael, S., Powers, E.T., Kelly, J.W., Roberts, A., Tong, G., Fang-Newmeyer, T., Parker, J., Holland, E.A., Zhang, D., Nakanishi, N., Chen, H.S., Wolosker, H., Wang, Y., Parsons, L.H., Ambasudhan, R., Masliah, E., Heinemann, S.F., Pina-Crespo, J.C., Lipton, S.A., Abeta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), E2518–E2527.
358. Tanik, S.A., Schultheiss, C.E., Volpicelli-Daley, L.A., Brunden, K.R., Lee, V.M., Lewy body-like alpha-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 288 (2013), 15194–15210.
359. Taylor, J.P., Hardy, J., Fischbeck, K.H., Toxic proteins in neurodegenerative disease. Science 296 (2002), 1991–1995.
360. Tran, H.T., Chung, C.H., Iba, M., Zhang, B., Trojanowski, J.Q., Luk, K.C., Lee, V.M., Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep. 7 (2014), 2054–2065.
361. Tsarbopoulos, A., Use of mass spectrometric approaches to tackle challenges in drug discovery: the beta-amyloid paradigm. J. Adv. Med. Res. (JAMR) 1 (2014), 78–83.
362. Tyedmers, J., Mogk, A., Bukau, B., Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 11 (2010), 777–788.
363. Uversky, V.N., Cooper, M.E., Bower, K.S., Li, J., Fink, A.L., Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 515 (2002), 99–103.
364. Uversky, V.N., Li, J., Fink, A.L., Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276 (2001), 10737–10744.
365. van Rooijen, B.D., Claessens, M.M., Subramaniam, V., Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism. PLoS ONE, 5, 2010, e14292.
366. Vargas, K.J., Makani, S., Davis, T., Westphal, C.H., Castillo, P.E., Chandra, S.S., Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 34 (2014), 9364–9376.
367. Vepsalainen, S., Parkinson, M., Helisalmi, S., Mannermaa, A., Soininen, H., Tanzi, R.E., Bertram, L., Hiltunen, M., Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J. Med. Genet., 2007, 44.
368. Vetrivel, K.S., Zhang, Y.W., Xu, H.X., Thinakaran, G., Pathological and physiological functions of presenilins. Mol. Neurodegener., 2006, 1.
369. Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S.J., Przedborski, S., Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 2837–2842.
370. Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., Meaney, D.F., Trojanowski, J.Q., Lee, V.M., Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 (2011), 57–71.
371. Vossel, K.A., Zhang, K., Brodbeck, J., Daub, A.C., Sharma, P., Finkbeiner, S., Cui, B.X., Mucke, L., Tau reduction prevents A beta-induced defects in axonal transport. Science, 330, 2010 198-U152.
372. Wagner, J., Ryazanov, S., Leonov, A., Levin, J., Shi, S., Schmidt, F., Prix, C., Pan-Montojo, F., Bertsch, U., Mitteregger-Kretzschmar, G., Geissen, M., Eiden, M., Leidel, F., Hirschberger, T., Deeg, A.A., Krauth, J.J., Zinth, W., Tavan, P., Pilger, J., Zweckstetter, M., Frank, T., Bahr, M., Weishaupt, J.H., Uhr, M., Urlaub, H., Teichmann, U., Samwer, M., Botzel, K., Groschup, M., Kretzschmar, H., Griesinger, C., Giese, A., Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 125 (2013), 795–813.
373. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Rowan, M.J., Selkoe, D.J., Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30 (2002), 552–557.
374. Walsh, D.M., Selkoe, D.J., Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Peptide Lett. 11 (2004), 213–228.
375. Walsh, D.M., Selkoe, D.J., Aβ oligomers – a decade of discovery. J. Neurochem. 101 (2007), 1172–1184.
376. Walter, J., Haass, C., Secretases as targets for beta-amyloid lowering drugs. Drug Dev. Res. 56 (2002), 201–210.
377. Wang, P., Yang, G., Mosier, D.R., Chang, P., Zaidi, T., Gong, Y.-D., Zhao, N.-M., Dominguez, B., Lee, K.-F., Gan, W.-B., Zheng, H., Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J. Neurosci. 25 (2005), 1219–1225.
378. Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L.T., Liao, J., Auclair, J.R., Johnson, D., Landeru, A., Simorellis, A.K., Ju, S., Cookson, M.R., Asturias, F.J., Agar, J.N., Webb, B.N., Kang, C., Ringe, D., Petsko, G.A., Pochapsky, T.C., Hoang, Q.Q., A soluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 17797–17802.
379. Watts, J.C., Giles, K., Oehler, A., Middleton, L., Dexter, D.T., Gentleman, S.M., DeArmond, S.J., Prusiner, S.B., Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19555–19560.
380. Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N., Rubinsztein, D.C., alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278 (2003), 25009–25013.
381. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A., Lansbury, P.T. Jr., NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996), 13709–13715.
382. Wilson, D.M., Binder, L.I., Polymerization of microtubule-associated protein tau under near-physiological conditions. J. Biol. Chem. 270 (1995), 24306–24314.
383. Wilson, D.M., Binder, L.I., Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150 (1997), 2181–2195.
384. Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., Pham, E., Masliah, E., Gage, F.H., Riek, R., In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 4194–4199.
385. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M., Biere, A.L., alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274 (1999), 19509–19512.
386. Xilouri, M., Brekk, O.R., Landeck, N., Pitychoutis, P.M., Papasilekas, T., Papadopoulou-Daifoti, Z., Kirik, D., Stefanis, L., Boosting chaperone-mediated autophagy in vivo mitigates alpha-synuclein-induced neurodegeneration. Brain 136 (2013), 2130–2146.
387. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W., Yankner, B.A., Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002), 600–606.
388. Yamada, K., Cirrito, J.R., Stewart, F.R., Jiang, H., Finn, M.B., Holmes, B.B., Binder, L.I., Mandelkow, E.M., Diamond, M.I., Lee, V.M., Holtzman, D.M., In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31 (2011), 13110–13117.
389. Yang, Q., She, H., Gearing, M., Colla, E., Lee, M., Shacka, J.J., Mao, Z., Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 323 (2009), 124–127.
390. Yasojima, K., Akiyama, H., McGeer, E.G., McGeer, P.L., Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297 (2001), 97–100.
391. Yuan, A., Kumar, A., Peterhoff, C., Duff, K., Nixon, R.A., Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 28 (2008), 1682–1687.
392. Zaheer, A., Zaheer, S., Thangavel, R., Wu, Y., Sahu, S.K., Yang, B., Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage. Brain Res. 1208 (2008), 192–203.
393. Zempel, H., Mandelkow, E., Lost after translation: missorting of Tau protein and consequences for Alzheimer disease. Trends Neurosci. 37 (2014), 721–732.
394. Zhang, W., Wang, T., Pei, Z., Miller, D.S., Wu, X., Block, M.L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.S., Zhang, J., Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 19 (2005), 533–542.
395. Zhao, J., Fu, Y.F., Yasvoina, M., Shao, P.Z., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, M., Berry, R., Binder, L., Vassar, R., beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 27 (2007), 3639–3649.
396. Zhou, W., Hurlbert, M.S., Schaack, J., Prasad, K.N., Freed, C.R., Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res. 866 (2000), 33–43.